JAMA Psychiatry. 2014 May;71(5):547-56. doi: 10.1001/jamapsychiatry.2013.4546.
IMPORTANCE: Relapse is highly prevalent following substance abuse treatments, highlighting the need for improved aftercare interventions. Mindfulness-based relapse prevention (MBRP), a group-based psychosocial aftercare, integrates evidence-based practices from mindfulness-based interventions and cognitive-behavioral relapse prevention (RP) approaches. OBJECTIVE: To evaluate the long-term efficacy of MBRP in reducing relapse compared with RP and treatment as usual (TAU [12-step programming and psychoeducation]) during a 12-month follow-up period. DESIGN, SETTING, AND PARTICIPANTS: Between October 2009 and July 2012, a total of 286 eligible individuals who successfully completed initial treatment for substance use disorders at a private, nonprofit treatment facility were randomized to MBRP, RP, or TAU aftercare and monitored for 12 months. Participants medically cleared for continuing care were aged 18 to 70 years; 71.5% were male and 42.1% were of ethnic/racial minority. INTERVENTIONS: Participants were randomly assigned to 8 weekly group sessions of MBRP, cognitive-behavioral RP, or TAU. MAIN OUTCOMES AND MEASURES: Primary outcomes included relapse to drug use and heavy drinking as well as frequency of substance use in the past 90 days. Variables were assessed at baseline and at 3-, 6-, and 12-month follow-up points. Measures used included self-report of relapse and urinalysis drug and alcohol screenings. RESULTS: Compared with TAU, participants assigned to MBRP and RP reported significantly lower risk of relapse to substance use and heavy drinking and, among those who used substances, significantly fewer days of substance use and heavy drinking at the 6-month follow-up. Cognitive-behavioral RP showed an advantage over MBRP in time to first drug use. At the 12-month follow-up, MBRP participants reported significantly fewer days of substance use and significantly decreased heavy drinking compared with RP and TAU. CONCLUSIONS AND RELEVANCE: For individuals in aftercare following initial treatment for substance use disorders, RP and MBRP, compared with TAU, produced significantly reduced relapse risk to drug use and heavy drinking. Relapse prevention delayed time to first drug use at 6-month follow-up, with MBRP and RP participants who used alcohol also reporting significantly fewer heavy drinking days compared with TAU participants. At 12-month follow-up, MBRP offered added benefit over RP and TAU in reducing drug use and heavy drinking. Targeted mindfulness practices may support long-term outcomes by strengthening the ability to monitor and skillfully cope with discomfort associated with craving or negative affect, thus supporting long-term outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01159535
重要性:物质滥用治疗后复发率很高,这突显了需要改进的后续护理干预措施。基于正念的复发预防(MBRP)是一种基于小组的心理社会后续护理,它整合了基于正念的干预和认知行为复发预防(RP)方法中的循证实践。 目的:在 12 个月的随访期间,评估 MBRP 与 RP 和常规治疗(TAU [12 步编程和心理教育])相比,在减少复发方面的长期疗效。 设计、地点和参与者:2009 年 10 月至 2012 年 7 月期间,共有 286 名符合条件的个体在一家私人非营利性治疗机构成功完成了物质使用障碍的初始治疗,他们在接受后续护理时被随机分配到 MBRP、RP 或 TAU 组,并在 12 个月内进行监测。有继续接受治疗医学许可的参与者年龄在 18 至 70 岁之间;71.5%为男性,42.1%为少数民族/种族。 干预措施:参与者被随机分配到 8 周的 MBRP、认知行为 RP 或 TAU 小组。 主要结果和测量:主要结果包括药物使用和重度饮酒的复发以及过去 90 天内的物质使用频率。在基线和 3、6 和 12 个月的随访点评估变量。使用的措施包括自我报告的复发和尿液药物和酒精筛查。 结果:与 TAU 相比,接受 MBRP 和 RP 治疗的参与者报告的物质使用和重度饮酒复发风险明显降低,并且在那些使用物质的人中,在 6 个月的随访中,物质使用和重度饮酒的天数明显减少。认知行为 RP 在首次药物使用时间上优于 MBRP。在 12 个月的随访中,MBRP 组报告的物质使用天数明显少于 RP 组和 TAU 组,重度饮酒也明显减少。 结论和相关性:对于初始物质使用障碍治疗后的后续护理中的个体,与 TAU 相比,RP 和 MBRP 显著降低了药物使用和重度饮酒的复发风险。复发预防在 6 个月的随访中延迟了首次药物使用的时间,使用酒精的 MBRP 和 RP 参与者报告的重度饮酒天数也明显少于 TAU 参与者。在 12 个月的随访中,MBRP 在减少药物使用和重度饮酒方面比 RP 和 TAU 提供了额外的益处。有针对性的正念实践可以通过增强监测和熟练应对与渴望或负面情绪相关的不适的能力,从而支持长期结果,从而支持长期结果。 试验注册:clinicaltrials.gov 标识符:NCT01159535
J Consult Clin Psychol. 2010-6
J Subst Abuse Treat. 2019-5
Drug Alcohol Depend. 2017-10-1
Curr Addict Rep. 2025-12
Eur J Investig Health Psychol Educ. 2025-6-12
Int J Methods Psychiatr Res. 2025-6
World J Psychiatry. 2025-5-19
Psychiatr Serv. 2014-3-1
Psychol Addict Behav. 2012-8-20
J Health Psychol. 1999-5
Drug Alcohol Depend. 2011-7-1
Exp Clin Psychopharmacol. 2011-4